First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

1. Balar, A.V.
2. Castellano, D.
3. O'Donnell, P.H.
4. Grivas, P.
5. Vuky, J.
6. Powles, T.
7. Plimack, E.R.
8. Hahn, N.M.
9. de Wit, R.
10. Pang, L.
11. Savage, M.J.
12. Perini, R.F.
13. Keefe, S.M.
14. Bajorin, D.
15. Bellmunt, J.